Bunyaratavej, Narong2009-05-272009-05-272005-10-16Bunyaratavej N. Monitoring of Risedronate by biochemical bone markers in clinical practice. Journal of the Medical Association of Thailand. 2005 Oct; 88(suppl 5): S34-6http://imsear.searo.who.int/handle/123456789/43210Chotmaihet Thangphaet.The study of trend of Risedronate 10 mg/day in menopausal women with a high level of resorptive bone marker (Betacrosslaps, CTx) by the following bone markers:Bone alkaline phosphatase (formation marker) total alkaline phosphatase (TAlP), NMID osteocalcin, undercarboxylated osteocalcin (UcOC) and procollagen type 1 carboxyl propeptides (PICP). Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal. The level of undercarboxylated osteocalcin was increased after one year of treatment; it may be a sign of vitamin K2 deficiency. The bone alkaline phosphatase was decreased at the end of 12 months and Procollagen type 1 carboxyl propeptides (PICP) of twelfth month changed significantly compared to the sixth months of treatment (p=0.001) The once week 70 mg/week group also changed of CTx the same as daily dose group.engAlkaline Phosphatase --drug effectsBiological Markers --analysisBone Density --drug effectsBone Density Conservation Agents --administration & dosageBone Resorption --drug therapyBone and Bones --drug effectsDrug MonitoringEtidronic Acid --administration & dosageFemaleHumansMiddle AgedOsteocalcin --drug effectsOsteoporosis, Postmenopausal --drug therapyPeptide Fragments --drug effectsProcollagen --drug effectsTime FactorsTreatment OutcomeVitamin K DeficiencyClinical Trial